4sc Ag

Bayer Intellectual Property Gmbh

Zentaris Ag

Bayer Schering Pharma Ag

Asta Medica, Aktiengesellschaft

Zentaris Gmbh

Baxter Healthcare Sa

Ziopharm Oncology, Inc.

Thomas Beckers

Thomas Maier

Thomas Baer

Thomas Bär

Mathias Schmidt

Astrid Zimmermann

Volker Gekeler

Matthias Vennemann

Petra Gimmnich

Klaus Pekari

Hemant Joshi

Swen Hölder

Armin Zülch

Bernhard Kutscher

Thomas Klenner

Michael Bernd

Frank Dullweber

Peter Emig

Bernd Nickel

Thomas Reissmann

Sarvesh S Patel

Rolf-Peter Hummel

Silke Baasner

Thomas Ciossek

Gerald Bacher

Martin Feth

Herwig Pongratz

Siavosh Mahboobi

Matthias Müller

Ulf Bömer

Hartmut Rehwinkel

Beate Schmidt

Ningshu Liu

Stuart Ince

J&uuml;rgen Engel

Christian Hesslinger

Jürgen Engel

Ulrich Graedler

Josef Stadlwieser

Steffen Weinbrenner

Peter Romeis

Björn Bartels

Gerrit Beneke

Eckhard G&uuml;nther

Florian Dehmel

Sabine Kuhr

Alfred Popp

Harald Hufsky

Frank-D Bohmer

Steffen Teller

Andrea Uecker

Vikas Gore

Kirsten Peters

Erik Bruyneel

Sachin Shivatare

Siegfried Schneider

Sunil Chavan

Armin Zuelch

Yogesh Munot

Umesh Bhise

Alexander Weber

Jürgen Volz

Beate Aue

Thomas Stengel

Uday Joshi

Dipak Harel

Gerhard Bacher

G&uuml;nter Kamp

Patricia-Marie Charpentier

Peter-Paul Emig

Günter Kamp

Andreas Strub

Bjoern Bartels

Kamlesh Padiya

Mahindra Makhija

Matthias Mueller

Juergen Volz

Astrid Leja

Matthias MÜLLER

Ulf BÖMER

Sarvesh A Patel

Yogesh S Munot

Sachin S Shivatare

Compounds of formula (I) a tautomer or stereoisomer thereof, or a salt thereof, wherein ring B and the imidazole to which it is fused, R4, R6 and R7 have the meanings as given in the description and the claims, are effective inhibitors of the Pi3K/Akt pathway.

Fused bicyclic imidazoles

Compounds of a certain formula (I), in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, are novel effective HDAC inhibitors. 

Sulfonylpyrroles

Fused pyrimidines

N-sulphonylpyrroles and their use as histone deacetylase inhibitors

Compounds of formula (I) a tautomer or stereoisomer thereof, or a salt thereof, wherein ring B and the pyrimidine to which it is fused, R4, R5, R6 and R7 have the meanings as given in the description and the claims, are effective inhibitors of the Pi3K/Akt pathway.

Fused bicyclic pyrimidines

Compounds of a certain formula (I) wherein R1, R2, R3, X, Y, r, s, t, u and v have the meanings as defined in the specification, and the salts, solvates and hydrates thereof are novel effective HDAC 6 inhibitors. 

N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds

The compounds of formula (I), wherein ring D and ring E together form a fused ring system selected from formula (II), (III), (IV), (V), (VI), (VII), and the salts of these compounds are novel, effective inhibitors of histone deacetylases. 

Tetrahydro-fused pyridines as histone deacetylase inhibitors

The invention relates to thiophene-imidazopyridine compounds according to formula (I), wherein the substituents and symbols are as defined in the description. The compounds are inhibitors of PIk1. 

Thiophene-imidazopyridines

Compounds of a certain formula I, in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, as well as salts thereof are novel effective HDAC inhibitors.

Sulphonylpyrroles as inhibitors of HDACs novel sulphonylpyrroles

Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors

Sulphonylpyrroles

The invention relates to novel pyrimidine derivatives of Formula (1) which are efficacious inhibitors of protein kinases, in particular of one or more isoforms of the protein kinase B/Akt.

4,6-disubstituted pyrimidines and their use as protein kinase inhibitors

Compounds of the formula I in which the substitutents have the definitions provided in the specification, are novel, effective HDAC inhibitors.

Growing community of inventors

Constance, Germany

Thomas Beckers